4,300 Shares in Perspective Therapeutics, Inc. (NYSE:CATX) Acquired by nVerses Capital LLC

nVerses Capital LLC bought a new stake in Perspective Therapeutics, Inc. (NYSE:CATX) during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund bought 4,300 shares of the company’s stock, valued at approximately $57,000.

Several other large investors have also modified their holdings of CATX. RIA Advisory Group LLC increased its position in shares of Perspective Therapeutics by 1,313.4% during the 1st quarter. RIA Advisory Group LLC now owns 106,853 shares of the company’s stock worth $127,000 after purchasing an additional 99,293 shares during the last quarter. Bleakley Financial Group LLC acquired a new position in shares of Perspective Therapeutics in the 1st quarter worth approximately $40,000. Vanguard Group Inc. boosted its position in shares of Perspective Therapeutics by 34.6% during the 1st quarter. Vanguard Group Inc. now owns 17,780,106 shares of the company’s stock worth $21,158,000 after purchasing an additional 4,566,356 shares during the period. Affinity Asset Advisors LLC acquired a new stake in Perspective Therapeutics in the 1st quarter valued at approximately $6,069,000. Finally, Janus Henderson Group PLC purchased a new stake in Perspective Therapeutics in the first quarter valued at approximately $15,511,000. Institutional investors and hedge funds own 54.66% of the company’s stock.

Perspective Therapeutics Trading Up 0.8 %

Shares of NYSE:CATX opened at $12.75 on Tuesday. Perspective Therapeutics, Inc. has a 52 week low of $2.20 and a 52 week high of $19.05. The firm has a 50 day moving average price of $13.88.

Perspective Therapeutics (NYSE:CATX) last posted its quarterly earnings results on Monday, August 12th. The company reported ($0.17) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.04. The business had revenue of $0.53 million during the quarter. On average, research analysts forecast that Perspective Therapeutics, Inc. will post -0.87 earnings per share for the current year.

Analysts Set New Price Targets

CATX has been the topic of several research reports. Cantor Fitzgerald reissued an “overweight” rating on shares of Perspective Therapeutics in a research note on Monday, September 9th. Royal Bank of Canada lowered their price objective on shares of Perspective Therapeutics from $29.00 to $27.00 and set an “outperform” rating for the company in a research note on Friday, August 16th. Truist Financial started coverage on shares of Perspective Therapeutics in a research note on Wednesday, September 25th. They set a “buy” rating and a $21.00 target price on the stock. Wedbush began coverage on shares of Perspective Therapeutics in a research report on Tuesday, October 1st. They issued an “outperform” rating and a $25.00 price target for the company. Finally, Bank of America assumed coverage on Perspective Therapeutics in a research report on Thursday, July 25th. They set a “buy” rating and a $24.00 price objective on the stock. Eight analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $21.43.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.